SAVA|Cassava Sciences Inc|Price:2.380|

More Details of Cassava Sciences Inc Company

Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, investigational treatments for central nervous system disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures. The Company's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.

Cassava Sciences Inc Info



Ticker SymbolSAVA

Company nameCassava Sciences Inc

IPO dateJul 14, 2000

CEOBarry (Richard J)

Number of employees30

Security typeOrdinary Share

Fiscal year-endJul 14

Address6801 N. Capital of Texas Highway

CityAUSTIN

Stock exchangeNASDAQ OMX - NASDAQ BASIC

CountryUnited States of America

Postal code78731

Phone15125012444

Websitehttps://www.cassavasciences.com/

Ticker SymbolSAVA

IPO dateJul 14, 2000

CEOBarry (Richard J)

Company Executives of Cassava Sciences Inc



Name

Name/Position

Position

Shareholding

Change

Mr. Richard J. (Rick) Barry

President, Chief Executive Officer, Director

938.06K

+49.94%

Mr. Eric J. Schoen

Chief Financial Officer

11.50K

--

Dr. Robert Z. Gussin, Ph.D.

Independent Director

10.62K

--

Mr. Michael J. O'Donnell, Esq.

Independent Director

6.87K

--

Dr. Patrick J. Scannon, M.D., Ph.D.

Independent Director

--

Mr. R. Christopher Cook

Chief Operating and Legal Officer

--

Dr. Claude Nicaise, M.D.

Independent Chairman of the Board

--

Mr. Pierre Gravier

Independent Director

--

Mr. Robert Anderson, Jr.

Independent Director

--

Ms. Freda Nassif

Chief Business Officer

--

Name

Name/Position

Position

Shareholding

Change

Mr. Richard J. (Rick) Barry

President, Chief Executive Officer, Director

938.06K

+49.94%

Mr. Eric J. Schoen

Chief Financial Officer

11.50K

--

Dr. Robert Z. Gussin, Ph.D.

Independent Director

10.62K

--

Mr. Michael J. O'Donnell, Esq.

Independent Director

6.87K

--

Dr. Patrick J. Scannon, M.D., Ph.D.

Independent Director

--

Mr. R. Christopher Cook

Chief Operating and Legal Officer

--

Revenue Breakdown

Relevant data have not been disclosed by the company yet.

Relevant data have not been disclosed by the company yet.

By Business

By Region

Relevant data have not been disclosed by the company yet.

Shareholding Stats

Updated: Sun, May 10

Shareholders

Shareholder Types

Shareholders

Proportion

Nachtrab (Matthew)

4.69%

Marshall Wace LLP

4.38%

Barbier (Remi)

4.28%

Vanguard Capital Management, LLC

4.00%

Two Sigma Investments, LP

3.31%

Other

79.35%

Shareholders

Proportion

Nachtrab (Matthew)

4.69%

Marshall Wace LLP

4.38%

Barbier (Remi)

4.28%

Vanguard Capital Management, LLC

4.00%

Two Sigma Investments, LP

3.31%

Other

79.35%

Shareholder Types

Shareholders

Proportion

Individual Investor

11.02%

Investment Advisor

10.69%

Investment Advisor/Hedge Fund

8.69%

Hedge Fund

6.47%

Research Firm

2.44%

Pension Fund

0.47%

Venture Capital

0.07%

Other

60.14%

Institutional Shareholding



Updated: Wed, Apr 1

Reporting Period

No. of institutions

Shares Held

Proportion

Change

2026Q1

331

16.29M

33.73%

-1.57M

2025Q4

337

14.09M

29.17%

-2.63M

2025Q3

336

12.08M

25.00%

-7.63M

2025Q2

354

21.06M

43.60%

-2.49M

2025Q1

363

22.22M

46.00%

-1.56M

2024Q4

360

23.73M

49.12%

+4.41M

2024Q3

371

20.81M

43.35%

+1.72M

2024Q2

372

16.74M

35.19%

-1.63M

2024Q1

372

14.95M

34.46%

-4.56M

2023Q4

382

18.11M

42.87%

+1.40M

Shareholder Activity



Name

Shares Held

Proportion

Change

Chg %

Date

Nachtrab (Matthew)

2.27M

4.69%

+2.27M

--

Aug 16, 2024

Marshall Wace LLP

2.12M

4.38%

+54.02K

+2.62%

Dec 31, 2025

Barbier (Remi)

2.07M

4.28%

+727.36K

+54.36%

Sep 30, 2024

Two Sigma Investments, LP

1.60M

3.31%

+70.70K

+4.63%

Dec 31, 2025

BlackRock Institutional Trust Company, N.A.

1.40M

2.89%

-2.62K

-0.19%

Dec 31, 2025

Barry (Richard J)

469.56K

0.97%

+117.39K

+33.33%

Mar 27, 2025

Geode Capital Management, L.L.C.

545.97K

1.13%

+8.07K

+1.50%

Dec 31, 2025

Susquehanna International Group, LLP

528.02K

1.09%

+146.00K

+38.22%

Dec 31, 2025

D. E. Shaw & Co., L.P.

469.33K

0.97%

+469.33K

--

Dec 31, 2025

Related ETFs



Updated: Sat, Dec 6

Name

Proportion

iShares Neuroscience and Healthcare ETF

0.23%

iShares Micro-Cap ETF

0.03%

Avantis US Small Cap Equity ETF

0.01%

Humankind US Stock ETF

0%

Nuveen ESG Small-Cap ETF

0%

iShares Core S&P Total U.S. Stock Market ETF

0%

Texas Capital Texas Small Cap Equity Index ETF

0%

ProShares UltraPro Russell2000

0%

Global X Russell 2000 Covered Call ETF

0%

State Street SPDR S&P Pharmaceuticals ETF

0%

iShares Neuroscience and Healthcare ETF

Proportion0.23%

iShares Micro-Cap ETF

Proportion0.03%

Avantis US Small Cap Equity ETF

Proportion0.01%

Humankind US Stock ETF

Proportion0%

Nuveen ESG Small-Cap ETF

Proportion0%

iShares Core S&P Total U.S. Stock Market ETF

Proportion0%

Texas Capital Texas Small Cap Equity Index ETF

Proportion0%

ProShares UltraPro Russell2000

Proportion0%

Global X Russell 2000 Covered Call ETF

Proportion0%

State Street SPDR S&P Pharmaceuticals ETF

Proportion0%

Dividend



A total of 0.00 USD has been distributed in dividends over the past 5 years.

Date

Dividend

Record Date

Payment Date

Ex-dividend Date

No Data

Stock Splits



Date

Ex-dividend Date

Type

Ratio

No Data

Date

Ex-dividend Date

Type

Ratio

No Data